KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Net Cash Flow (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Net Cash Flow data on record, last reported at $610.9 million in Q4 2025.

  • For Q4 2025, Net Cash Flow rose 27.83% year-over-year to $610.9 million; the TTM value through Dec 2025 reached $634.4 million, up 355.7%, while the annual FY2025 figure was $634.4 million, 355.7% up from the prior year.
  • Net Cash Flow reached $610.9 million in Q4 2025 per REGN's latest filing, up from $497.9 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $809.4 million in Q1 2023 and bottomed at -$2.0 billion in Q2 2023.
  • Average Net Cash Flow over 5 years is -$31.2 million, with a median of $96.2 million recorded in 2022.
  • Peak YoY movement for Net Cash Flow: tumbled 4105.47% in 2023, then skyrocketed 573.25% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at -$756.9 million in 2021, then soared by 49.08% to -$385.4 million in 2022, then soared by 249.82% to $577.4 million in 2023, then fell by 17.23% to $477.9 million in 2024, then increased by 27.83% to $610.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were $610.9 million in Q4 2025, $497.9 million in Q3 2025, and -$1.1 billion in Q2 2025.